Market Overview

Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma

Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma

The strategy in pharmaceuticals has switched from blockbuster M&A deals towards smaller targets. This trend highlights increased drug approvals by the FDA. Drug approvals have continued to grow year on year.

"We expect approvals to remain relatively strong in the intermediate term, despite lagging during the first four months of 2016," Fitch reported.

Related Link: What's M&A Like In The Biotech Sector Right Now?

Big pharma is looking for smaller biotech and therapeutics companies to increase their drug portfolios. With big M&A deals being in a very critical environment, this seems to be the winning strategy for large firms. Even with acquisitions, companies will still focus on "innovative treatment platforms" due to "positive trends in drug development pipelines, new product commercialization and moderating patent expiry risks," Fitch noted.

Recent Big Pharma acquisitions

  • Pfizer Inc. (NYSE: PFE) announced it would buy Anacor Pharmaceuticals Inc. (NASDAQ: ANAC).
  • Bristol-Myers Squibb's Co (NYSE: BMY) acquisition of Padlock therapeutics.
  • Eli Lilly and Co's (NYSE: LLY) acquisition of Glycostasis Inc.

Related Articles (BMY + PFE)

View Comments and Join the Discussion!

Posted-In: FitchAnalyst Color Biotech M&A News Health Care General

Latest Ratings

JBLRBC CapitalMaintains38.0
COSTRBC CapitalMaintains412.0
COSTMKM PartnersMaintains325.0
MTNTruist SecuritiesMaintains243.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at